Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model

Terufumi Yoshida; Masaki Kaibori; Nanami Fujisawa; Mariko Ishizuka; Fusao Sumiyama; Masahiko Hatta; Hisashi Kosaka; Kosuke Matsui; Kensuke Suzuki; Tomoya O. Akama; Tayo Katano; Kengo Yoshii; Mitsuhiro Ebara; Mitsugu Sekimoto

doi:10.3390/nano12081364

Nanomaterials (Apr 2022)

Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model

Terufumi Yoshida,
Masaki Kaibori,
Nanami Fujisawa,
Mariko Ishizuka,
Fusao Sumiyama,
Masahiko Hatta,
Hisashi Kosaka,
Kosuke Matsui,
Kensuke Suzuki,
Tomoya O. Akama,
Tayo Katano,
Kengo Yoshii,
Mitsuhiro Ebara,
Mitsugu Sekimoto

Affiliations

Terufumi Yoshida: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan
Masaki Kaibori: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan
Nanami Fujisawa: Research Center for Functional Materials, National Institute for Materials Science (NIMS), Tsukuba 305-0044, Japan
Mariko Ishizuka: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan
Fusao Sumiyama: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan
Masahiko Hatta: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan
Hisashi Kosaka: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan
Kosuke Matsui: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan
Kensuke Suzuki: Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Hirakata 573-1010, Japan
Tomoya O. Akama: Department of Pharmacology, Kansai Medical University, Hirakata 573-1010, Japan
Tayo Katano: Department of Medical Chemistry, Kansai Medical University, Hirakata 573-1010, Japan
Kengo Yoshii: Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan
Mitsuhiro Ebara: Research Center for Functional Materials, National Institute for Materials Science (NIMS), Tsukuba 305-0044, Japan
Mitsugu Sekimoto: Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan

DOI: https://doi.org/10.3390/nano12081364
Journal volume & issue: Vol. 12, no. 8
p. 1364

Abstract

Read online

Lenvatinib has a high response rate in unresectable advanced hepatocellular carcinoma (HCC). In this study, we investigated whether lenvatinib-incorporating poly(ε-caprolactone) sheets (lenvatinib sheets) as a drug delivery system (DDS) exerted antitumor effects in a murine HCC model. The lenvatinib sheets were designed for sustained release of approximately 1 mg lenvatinib for 14 days. For 14 days, 1 mg lenvatinib was orally administered to mice. Then, we compared the antitumor effects of lenvatinib sheets with those of oral lenvatinib. The tumor volume, body weight, and serum lenvatinib level were measured for 14 days. A peritoneal dissemination model was established to examine the survival prolongation effect of the lenvatinib sheets. Tumor growth was significantly inhibited in the lenvatinib sheet group compared with that in the no treatment and oral groups. The antitumor effect was significantly higher in the lenvatinib sheet group. Regardless of the insertion site, the serum lenvatinib levels were maintained and showed similar antitumor effects. The mitotic index was significantly inhibited in the lenvatinib sheet group compared with that in the control group. Furthermore, lenvatinib sheets improved the 30-day survival. Lenvatinib sheets showed sufficient antitumor effects and may serve as an effective novel DDS for advanced HCC.

Published in Nanomaterials

ISSN: 2079-4991 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Chemistry
Website: https://www.mdpi.com/journal/nanomaterials

About the journal

Abstract

Keywords